220 Results (Page 1 of 19)
Spain Markets Research Reports
Spain Multiple Myeloma Therapeutics Market Analysis
The Spain Multiple Myeloma Therapeutics Market was valued at $161 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 3.5% from 2022 to 2030 and will reach $212 Mn in 2030. One of the main reasons propelling the growth of this Market is increase in Introduction of innovative therapies, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Janssen-Cilag S.A, Celgene, Amgen, Takeda, Laboratories Rovi, and others.
Spain Clinical Diagnostics Market Analysis
Spain's clinical diagnostic market was valued at $1.3 Bn in 2022 and is estimated to expand at a CAGR of 5% from 2022-30 and will reach $1.9 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and government support. The market is segmented by type, drug, and distribution channel. Some key players in this market are Abbott, BD, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, Siemens AG, Hologic, Qiagen NV, Quest Diagnostics, F. Hoffmann-La Roche Ltd, Eurofins Megalab, Werfen Group, Grifols and others.
Spain Vitamin and Minerals Market Analysis
This report presents a strategic analysis of the Spain Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain Vitamin and Minerals Market, offering unmatched value, accuracy and expert insights.
Spain Patient Support Programs (PSP) Market Analysis
Spain's Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 8.9% for the year 2022-30. Continuous monitoring and assistance required for the management of chronic diseases and the implementation of smarter technologies in Spain are driving the Spain Patient Support Programs (PSP) market. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and the end user. Some of the major PSP operators in the Spain Patient Support Programs (PSP) market include Ashfield Engage, Evidenze, and Clover
Spain Oral Care Market Analysis
Spain's oral care market was valued at $680 Mn in 2022 and is estimated to expand at a CAGR of 5.2% from 2022-30 and will reach $1020 Mn in 2030. One of the main reasons propelling the growth of this market is the rising demand for premium oral care products and the ageing population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Vitaldent, Adeslas Dental, Sanitas Dental, Dentsply Sirona, BioHorizons, Kerr, GC Europe, Septodont, and Sirona.
Spain Healthcare Claims Management Market Analysis
Spain's healthcare claims management market is projected to grow from $515.31 Mn in 2022 to $2596.09 Mn by 2030, registering a CAGR of 22.4% during the forecast period of 2022-30. The main factors driving the growth would be the increasing prevalence of chronic diseases, regulatory changes, technological advancements and increasing healthcare spending. The market is segmented by component, type, delivery mode and by end-user. Some of the major players include Hinrichs Software, Veta+, Asitur, GE Healthcare, Cognizant and Allianz Care.
Spain Artificial Intelligence (AI) in Diagnostics Market Analysis
Spain's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $0.02 Bn in 2022 to $0.20 Bn by 2030, registering a CAGR of 34% during the forecast period of 2022-30. The market will be driven by increasing demand for more accurate and efficient diagnostic solutions and positive government initiatives. The market is segmented by component & by diagnosis. Some of the major players include GE Healthcare, IBM Watson Health & QUIBIM.
Spain 3D Printing Medical Devices Market Analysis
Spain's 3D printing medical devices market size was valued at $57 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 15.3% from 2022-30 and will reach $179 Mn in 2030. The market is segmented by component, application, technology, and end user. This market will grow medical devices manufactured to order using 3D printing providing new opportunities for improving patient care and creating ground-breaking treatments. The key market players are BCN3D Technologies (ESP), Regemat3D (ESP), EMO3D (ESP), Intamsys (ESP), Nanofabrica (ESP), Grupo Sicnova (ESP), Microlay (ESP), Zerintia Technologies (ESP), Mimetis Biomaterials (ESP), 3D Surgical Technologies (ESP), Dental Global Service (ESP), and others.
Spain Dental Care Market Analysis
Spain's dental care market size is at around $692.48 Mn in 2022 and is projected to reach $1,054.71 Mn in 2030, exhibiting a CAGR of 5.4% during the forecast period of 2022-30. Emerging as the most attractive market of dental care tourism in Europe Post-Brexit is stirred by the change in corporate lead ownership of dental practices by key players like Dentix, Clínicas, Dentales Sanitas, Clínicas Dentales Fidentia. This report by is segmented by treatment type, age group, clinical setup, and demography and provides in-depth insights for corporations to target their competitive position in Spain’s dental services market.
Spain Morquio Syndrome (MPS-IV) Therapeutics Market Analysis
Spain Morquio Syndrome (MPS-IV) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Major global players in Morquio Syndrome (MPS-IV) Therapeutics Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.
Spain Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
Spain Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Spain Multiple Myeloma Therapeutics Market Analysis
Spain multiple myeloma therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of the illness, new technologies, and improved healthcare systems are a few of the elements boosting the revenue of the worldwide multiple myeloma market. Major global players in this market are Teva Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Genentech Inc. (F. Hoffmann-La Roche Ltd) Novartis AG Celgene Corporation (Bristol Myers Squibb Company) Janssen Pharmaceuticals Inc. (Johnson & Johnson) AbbVie Inc. Ono Pharmaceutical Co. Ltd. Sanofi S.A. Pfizer Inc. Merck & Co. Inc. Eli Lilly and Company Cipla Inc
Spain Multiple Sclerosis Therapeutics Market Analysis
Spain multiple sclerosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. These are the two reasons propelling market expansion. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)
Spain Myasthenia Gravis Therapeutics Market Analysis
Spain myasthenia gravis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The myasthenia gravis market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
Spain Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
Spain Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favourable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.
Spain Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
Spain Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
Spain Narcolepsy Therapeutics Market Analysis
Spain narcolepsy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an ageing population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in Narcolepsy Therapeutics Market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.
Spain Neuroendocrine Tumor Therapeutics Market Analysis
Spain neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Analysis
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS) are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
Spain Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis
Spain Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.
Spain Optic Neuritis Therapeutics Market Analysis
Spain Optic Neuritis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rising incidence of optic neuritis is anticipated to fuel market expansion on a global scale. The rising prevalence of multiple sclerosis may be a major market driver. The usage of intravenous steroids such as prednisone, prednisolone, and others are anticipated to increase, which will help support market expansion. Major global players in Optic Neuritis Therapeutics Market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma.
Spain Ovarian Cancer Therapeutics Market Analysis
Spain Ovarian Cancer Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors driving the growth of the ovarian cancer market is the rising prevalence of the disease. Other important drivers are the development of new therapies and treatments, rising healthcare expenses, and increased government support. Due to greater public awareness of healthcare issues, the market for ovarian cancer is also expanding. Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.
Spain Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis
Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.
Spain Phenylketonuria Therapeutics Market Analysis
Spain Phenylketonuria Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for phenylketonuria therapeutics is being driven by a variety of factors, including the increasing prevalence of PKU, technological advancements in PKU diagnostics, government initiatives and funding, and growing patient demand for effective treatments for the condition. Major global players in Phenylketonuria Therapeutics Market are DAIICHI SANKYO COMPANY, LIMITED, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., SOM BIOTECH, S.L. Healthcare, Synthetic Biologics, Inc., Nestl?, Codexis, BioMarin, Erytech Pharma.,
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc